Contrast Media/Contrast Agents Market by Product, by Procedure, by Application - Global Forecasts to 2020
出 版 商：MicroMarketMonitor?
出版日期：2015/07/06
頁 數：166頁
文件格式：PDF
價 格：
USD 4,250 (Single-User License)
USD 5,150 (Multi-User License)
USD 8,150 (Global-User License)
USD 5,150 (Multi-User License)
USD 8,150 (Global-User License)
Over the years, the contrast media/contrast agents market has witnessed various advancements in products and their approvals to meet the needs of patients and radiologists worldwide. These advancements have led to the improved use of many existing contrast agents as well as the introduction of new ones.
In 2015, the iodinated contrast media/contrast agents are expected to account for the largest share of the global contrast media/contrast agents market, among products; the injectable contrast media segment is expected to account for the largest share of the global contrast media/contrast agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media/contrast agents market, among procedures; cardiovascular disorders is expected to account for the largest share of the global contrast media/contrast agents market, among indications; and the radiology segment is expected to dominate the contrast media/contrast agents market, among applications.
In 2015, North America is estimated to be the largest market for contrast media/contrast agents, globally, followed by Europe, Asia-Pacific, and Rest of the World (RoW). In the coming years, the contrast media/contrast agents market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in this region can be attributed to the increasing research & development investments, expansion of international players, the increasing incidences of disease, and favorable regulatory frameworks.
The global contrast media/ contrast agents market has witnessed high competitive intensity in recent years, with Bayer Healthcare (Germany) and GE Healthcare (U.K.) being the leading market players. Other players include Guerbet Group (France), Bracco Imaging S.p.A. (Italy), Mallinckrodt PLC (Ireland), and Lantheus Medical Imaging (U.S.), among others. The players in this market have implemented various strategies to expand their global footprint and increase their market shares. The key strategies followed by most of the companies in the contrast media market include agreements, partnerships, strategic alliances, collaborations, corporate alliances/contracts; market development; and expansions; among others.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater share of the concerned market. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios offered by the top players in the contrast media/contrast agents market - the report analyzes the contrast media/contrast agents market, on the basis of product, route of administration, procedure, indication, and application
‧ Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, product approvals, and new product launches in the contrast media/contrast agents market
‧ Market Development: Comprehensive information about the lucrative emerging markets - the report analyzes the markets for various contrast media/contrast agents across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the contrast media/contrast agents market
‧ Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the contrast media/contrast agents market
In 2015, the iodinated contrast media/contrast agents are expected to account for the largest share of the global contrast media/contrast agents market, among products; the injectable contrast media segment is expected to account for the largest share of the global contrast media/contrast agents market, among the routes of administration; the X-ray/CT segment is expected to dominate the global contrast media/contrast agents market, among procedures; cardiovascular disorders is expected to account for the largest share of the global contrast media/contrast agents market, among indications; and the radiology segment is expected to dominate the contrast media/contrast agents market, among applications.
In 2015, North America is estimated to be the largest market for contrast media/contrast agents, globally, followed by Europe, Asia-Pacific, and Rest of the World (RoW). In the coming years, the contrast media/contrast agents market is expected to witness the highest growth rate in the Asia-Pacific region. The high growth in this region can be attributed to the increasing research & development investments, expansion of international players, the increasing incidences of disease, and favorable regulatory frameworks.
The global contrast media/ contrast agents market has witnessed high competitive intensity in recent years, with Bayer Healthcare (Germany) and GE Healthcare (U.K.) being the leading market players. Other players include Guerbet Group (France), Bracco Imaging S.p.A. (Italy), Mallinckrodt PLC (Ireland), and Lantheus Medical Imaging (U.S.), among others. The players in this market have implemented various strategies to expand their global footprint and increase their market shares. The key strategies followed by most of the companies in the contrast media market include agreements, partnerships, strategic alliances, collaborations, corporate alliances/contracts; market development; and expansions; among others.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater share of the concerned market. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the product portfolios offered by the top players in the contrast media/contrast agents market - the report analyzes the contrast media/contrast agents market, on the basis of product, route of administration, procedure, indication, and application
‧ Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, product approvals, and new product launches in the contrast media/contrast agents market
‧ Market Development: Comprehensive information about the lucrative emerging markets - the report analyzes the markets for various contrast media/contrast agents across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the contrast media/contrast agents market
‧ Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the contrast media/contrast agents market
TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.1.1 Key data from secondary sources 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key industry insights 23
2.2.2.2 Key data from primary sources 24
2.2.2.3 Key insights from primary sources 25
2.3 MARKET SIZE ESTIMATION METHODOLOGY 25
2.3.1 MARKET FORECAST METHODOLOGY 27
2.4 MARKET DATA VALIDATION AND TRIANGULATION 28
2.5 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CURRENT SCENARIO 30
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 34
4 PREMIUM INSIGHTS 35
4.1 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET 35
4.2 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT AND ROUTE OF ADMINISTRATION 36
4.3 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION (2015 VS. 2020) 37
?
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.3 MARKET DYNAMICS 40
5.3.1 DRIVERS 40
5.3.1.1 Increase in demand for diagnostics & image guided procedures influences the sales of contrast media 40
5.3.1.2 Increasing approvals for contrast agents 40
5.3.1.3 Increase in the number of public and private diagnostic centers to improve diagnostic imaging services 41
5.3.1.4 Rising number of cancer patients responsible for increasing the number of diagnostic procedures 41
5.3.1.5 Increasing prevalence of diseases associated with the growth in the aging population is driving the demand of various diagnostic imaging modalities 42
5.3.1.6 Improving healthcare infrastructure in emerging markets 42
5.3.2 RESTRAINTS 44
5.3.2.1 Risk associated with contrast agents 44
5.3.2.2 Need for highly skilled professionals 45
5.3.3 OPPORTUNITIES 46
5.3.3.1 Strong product pipeline likely to boost the contrast media market 46
5.3.3.2 Increasing research on contrast agent and their applications 47
5.3.4 CHALLENGES 49
5.3.4.1 Development of gamma and neutron imaging solutions 49
6 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT 50
6.1 INTRODUCTION 51
6.2 BARIUM- BASED CONTRAST MEDIA 52
6.2.1 INTRODUCTION 52
6.2.2 ADVANTAGES 52
6.2.3 DISADVANTAGES 52
6.3 IODINATED CONTRAST MEDIA 54
6.3.1 INTRODUCTION 54
6.3.2 TYPES 54
6.3.3 LIMITATIONS 55
6.4 GADOLINIUM BASED CONTRAST MEDIA 56
6.5 MICROBUBBLES 57
?
7 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY MEDICAL PROCEDURE 59
7.1 INTRODUCTION 60
7.2 X-RAY/CT 62
7.3 MRI 63
7.4 ULTRASOUND 64
8 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION 66
8.1 INTRODUCTION 67
8.2 ORAL CONTRAST MEDIA 68
8.3 INJECTABLE CONTRAST MEDIA 69
8.4 RECTAL CONTRAST MEDIA 70
8.5 URETHRAL CONTRAST MEDIA 71
9 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION 73
9.1 INTRODUCTION 74
9.2 CARDIOVASCULAR DISORDERS 75
9.3 ONCOLOGY 77
9.4 GASTROINTESTINAL DISORDERS 78
9.5 NEUROLOGICAL DISORDERS 79
9.6 NEPHROLOGICAL DISORDERS 80
9.7 MUSCULOSKELETAL DISORDERS 81
10 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY APPLICATION 82
10.1 INTRODUCTION 83
10.2 RADIOLOGY 85
10.3 INTERVENTIONAL RADIOLOGY 86
10.4 INTERVENTIONAL CARDIOLOGY 87
11 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY REGION 88
11.1 INTRODUCTION 89
11.2 NORTH AMERICA 91
11.2.1 U.S. 94
11.2.1.1 Increase in the number of diagnostic imaging centers 94
11.2.1.2 Increase in the ageing population and rising prevalence of chronic diseases in the U.S. 94
11.2.1.3 Reimbursement cuts under Obama care 95
11.2.2 CANADA 98
11.2.2.1 High incidence rate of cancer, cardiovascular diseases and diabetes in Canada 98
11.2.2.2 Increasing MRI and CT examinations and government funding to boost the Canadian market 98
11.3 EUROPE 102
11.3.1 EU5 106
11.3.1.1 Increase in investment by market players 106
11.3.1.2 Increasing incidence and prevalence of cancer 106
11.3.1.3 Healthcare spending rises but remains weak in EU5 countries 107
11.3.1.4 Shortage of medical imaging instruments/Scanners likely to hamper the U.K. market 107
11.3.2 ROE 110
11.3.2.1 Increase focus of market players in ROE Countries 110
11.3.2.2 Increasing number of MRI and CT scanners 110
11.4 ASIA-PACIFIC 114
11.4.1 RISE IN THE AGEING POPULATION AND INCREASING CANCER INCIDENCE 114
11.4.2 RISING NUMBER OF DIAGNOSTIC FACILITIES/PROCEDURES IN JAPAN 114
11.4.3 EXPANSION OF INTERNATIONAL PLAYERS IN CHINA AND INDIA 115
11.4.4 INCREASING R&D INVESTMENTS IN CHINA 115
11.4.5 FAVOURABLE REGULATORY CHANGES TO INCREASE THE MARKET IN NEW ZEALAND AND AUSTRALIA 116
11.5 REST OF THE WORLD 119
11.5.1 LATIN AMERICA 119
11.5.2 THE MIDDLE EAST 120
11.5.3 AFRICA 120
12 COMPETITIVE LANDSCAPE 124
12.1 OVERVIEW 124
12.2 MARKET SHARE ANALYSIS, CONTRAST MEDIA/ CONTRAST AGENTS MARKET (2014) 125
12.2.1 BAYER HEALTHCARE 126
12.2.2 GE HEALTHCARE 126
12.3 COMPETITIVE SITUATION AND TRENDS 127
12.3.1 MARKET DEVELOPMENT (PRODUCT APPROVALS) 128
12.3.2 AGREEMENTS/ COLLABORATIONS/ PARTNERSHIPS/ STRATEGIC ALLIANCES/ CONTRACTS/ CORPORATE ALLIANCES 129
12.3.3 DIVESTMENTS /INVESTMENTS 131
12.3.4 EXPANSIONS 132
12.3.5 OTHERS 133
?
13 COMPANY PROFILES 135
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 GE HEALTHCARE 135
13.2 BAYER HEALTHCARE 138
13.3 BRACCO IMAGING S.P.A. (A SUBSIDIARY OF BRACCO S.P.A.) 141
13.4 GUERBET GROUP 143
13.5 MALLINCKRODT PLC 146
13.6 LANTHEUS MEDICAL IMAGING 148
13.7 NANOPET PHARMA GMBH 150
13.8 CMC CONTRAST AB 152
13.9 TARGESON, INC. PHARMA CO., LTD. 153
13.10 DAIICHI SANKYO 154
13.11 SUBHRA PHARMA PRIVATE LIMITED 156
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
14 APPENDIX 157
14.1 DISCUSSION GUIDE 157
14.2 MORE COMPANY DEVELOPMENTS (2012-2015) 161
14.2.1 GE HEALTHCARE 161
14.2.2 BAYER HEALTHCARE 162
14.2.3 BRACCO IMAGING S.P.A. 162
14.2.4 GUERBET LLC 163
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 164
14.4 AVAILABLE CUSTOMIZATIONS 164
14.5 RELATED REPORTS 165
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 RESEARCH METHODOLOGY STEPS 20
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 21
2.2.1 SECONDARY RESEARCH 21
2.2.1.1 Key data from secondary sources 21
2.2.2 PRIMARY RESEARCH 22
2.2.2.1 Key industry insights 23
2.2.2.2 Key data from primary sources 24
2.2.2.3 Key insights from primary sources 25
2.3 MARKET SIZE ESTIMATION METHODOLOGY 25
2.3.1 MARKET FORECAST METHODOLOGY 27
2.4 MARKET DATA VALIDATION AND TRIANGULATION 28
2.5 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
3.1 INTRODUCTION 29
3.2 CURRENT SCENARIO 30
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 34
4 PREMIUM INSIGHTS 35
4.1 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET 35
4.2 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT AND ROUTE OF ADMINISTRATION 36
4.3 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION (2015 VS. 2020) 37
?
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.3 MARKET DYNAMICS 40
5.3.1 DRIVERS 40
5.3.1.1 Increase in demand for diagnostics & image guided procedures influences the sales of contrast media 40
5.3.1.2 Increasing approvals for contrast agents 40
5.3.1.3 Increase in the number of public and private diagnostic centers to improve diagnostic imaging services 41
5.3.1.4 Rising number of cancer patients responsible for increasing the number of diagnostic procedures 41
5.3.1.5 Increasing prevalence of diseases associated with the growth in the aging population is driving the demand of various diagnostic imaging modalities 42
5.3.1.6 Improving healthcare infrastructure in emerging markets 42
5.3.2 RESTRAINTS 44
5.3.2.1 Risk associated with contrast agents 44
5.3.2.2 Need for highly skilled professionals 45
5.3.3 OPPORTUNITIES 46
5.3.3.1 Strong product pipeline likely to boost the contrast media market 46
5.3.3.2 Increasing research on contrast agent and their applications 47
5.3.4 CHALLENGES 49
5.3.4.1 Development of gamma and neutron imaging solutions 49
6 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY PRODUCT 50
6.1 INTRODUCTION 51
6.2 BARIUM- BASED CONTRAST MEDIA 52
6.2.1 INTRODUCTION 52
6.2.2 ADVANTAGES 52
6.2.3 DISADVANTAGES 52
6.3 IODINATED CONTRAST MEDIA 54
6.3.1 INTRODUCTION 54
6.3.2 TYPES 54
6.3.3 LIMITATIONS 55
6.4 GADOLINIUM BASED CONTRAST MEDIA 56
6.5 MICROBUBBLES 57
?
7 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY MEDICAL PROCEDURE 59
7.1 INTRODUCTION 60
7.2 X-RAY/CT 62
7.3 MRI 63
7.4 ULTRASOUND 64
8 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY ROUTE OF ADMINISTRATION 66
8.1 INTRODUCTION 67
8.2 ORAL CONTRAST MEDIA 68
8.3 INJECTABLE CONTRAST MEDIA 69
8.4 RECTAL CONTRAST MEDIA 70
8.5 URETHRAL CONTRAST MEDIA 71
9 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY INDICATION 73
9.1 INTRODUCTION 74
9.2 CARDIOVASCULAR DISORDERS 75
9.3 ONCOLOGY 77
9.4 GASTROINTESTINAL DISORDERS 78
9.5 NEUROLOGICAL DISORDERS 79
9.6 NEPHROLOGICAL DISORDERS 80
9.7 MUSCULOSKELETAL DISORDERS 81
10 GLOBAL CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY APPLICATION 82
10.1 INTRODUCTION 83
10.2 RADIOLOGY 85
10.3 INTERVENTIONAL RADIOLOGY 86
10.4 INTERVENTIONAL CARDIOLOGY 87
11 CONTRAST MEDIA/ CONTRAST AGENTS MARKET, BY REGION 88
11.1 INTRODUCTION 89
11.2 NORTH AMERICA 91
11.2.1 U.S. 94
11.2.1.1 Increase in the number of diagnostic imaging centers 94
11.2.1.2 Increase in the ageing population and rising prevalence of chronic diseases in the U.S. 94
11.2.1.3 Reimbursement cuts under Obama care 95
11.2.2 CANADA 98
11.2.2.1 High incidence rate of cancer, cardiovascular diseases and diabetes in Canada 98
11.2.2.2 Increasing MRI and CT examinations and government funding to boost the Canadian market 98
11.3 EUROPE 102
11.3.1 EU5 106
11.3.1.1 Increase in investment by market players 106
11.3.1.2 Increasing incidence and prevalence of cancer 106
11.3.1.3 Healthcare spending rises but remains weak in EU5 countries 107
11.3.1.4 Shortage of medical imaging instruments/Scanners likely to hamper the U.K. market 107
11.3.2 ROE 110
11.3.2.1 Increase focus of market players in ROE Countries 110
11.3.2.2 Increasing number of MRI and CT scanners 110
11.4 ASIA-PACIFIC 114
11.4.1 RISE IN THE AGEING POPULATION AND INCREASING CANCER INCIDENCE 114
11.4.2 RISING NUMBER OF DIAGNOSTIC FACILITIES/PROCEDURES IN JAPAN 114
11.4.3 EXPANSION OF INTERNATIONAL PLAYERS IN CHINA AND INDIA 115
11.4.4 INCREASING R&D INVESTMENTS IN CHINA 115
11.4.5 FAVOURABLE REGULATORY CHANGES TO INCREASE THE MARKET IN NEW ZEALAND AND AUSTRALIA 116
11.5 REST OF THE WORLD 119
11.5.1 LATIN AMERICA 119
11.5.2 THE MIDDLE EAST 120
11.5.3 AFRICA 120
12 COMPETITIVE LANDSCAPE 124
12.1 OVERVIEW 124
12.2 MARKET SHARE ANALYSIS, CONTRAST MEDIA/ CONTRAST AGENTS MARKET (2014) 125
12.2.1 BAYER HEALTHCARE 126
12.2.2 GE HEALTHCARE 126
12.3 COMPETITIVE SITUATION AND TRENDS 127
12.3.1 MARKET DEVELOPMENT (PRODUCT APPROVALS) 128
12.3.2 AGREEMENTS/ COLLABORATIONS/ PARTNERSHIPS/ STRATEGIC ALLIANCES/ CONTRACTS/ CORPORATE ALLIANCES 129
12.3.3 DIVESTMENTS /INVESTMENTS 131
12.3.4 EXPANSIONS 132
12.3.5 OTHERS 133
?
13 COMPANY PROFILES 135
(Overview, Financials, Products & Services, Strategy, & Developments)*
13.1 GE HEALTHCARE 135
13.2 BAYER HEALTHCARE 138
13.3 BRACCO IMAGING S.P.A. (A SUBSIDIARY OF BRACCO S.P.A.) 141
13.4 GUERBET GROUP 143
13.5 MALLINCKRODT PLC 146
13.6 LANTHEUS MEDICAL IMAGING 148
13.7 NANOPET PHARMA GMBH 150
13.8 CMC CONTRAST AB 152
13.9 TARGESON, INC. PHARMA CO., LTD. 153
13.10 DAIICHI SANKYO 154
13.11 SUBHRA PHARMA PRIVATE LIMITED 156
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
14 APPENDIX 157
14.1 DISCUSSION GUIDE 157
14.2 MORE COMPANY DEVELOPMENTS (2012-2015) 161
14.2.1 GE HEALTHCARE 161
14.2.2 BAYER HEALTHCARE 162
14.2.3 BRACCO IMAGING S.P.A. 162
14.2.4 GUERBET LLC 163
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 164
14.4 AVAILABLE CUSTOMIZATIONS 164
14.5 RELATED REPORTS 165
